Granules India Share Price Valuation Analysis April 2026
Founded in 1984 by Krishna Prasad Chigurupati in Hyderabad, Granules India has evolved from a single-molecule paracetamol API producer into one of India’s most distinctive vertically integrated generic pharmaceutical manufacturers. The company operates across three primary revenue streams — Active Pharmaceutical Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Finished Dosages (FD) — across 10 manufacturing facilities (7 in India, 2 in the US, 1 in Switzerland).
Granules’ product-focused model concentrates on high-volume, first-line generic molecules: paracetamol, ibuprofen, metformin, guaifenesin, and methocarbamol. The company holds an estimated ~50% US market share in ibuprofen, acetaminophen, and metformin combined — a structural competitive advantage rooted in scale and process efficiency. In FY26, finished dosages account for 76% of revenues, PFI 11%, and API 11%, with a nascent peptides/CDMO segment (Ascelis Peptides, acquired Senn Chemicals AG in 2025) contributing ~2%.
North America is the dominant geography, contributing 79% of Q4 FY25 revenues. The strategic pivot from bulk API supply to branded and OTC finished dosages in the US (via Granules Consumer Health and the GPI prescription label) has structurally re-rated margins. Granules Life Sciences (GLS), the newest formulations facility, commenced commercial dispatches in FY24 with a planned capacity of 10 billion units annually.
| Year (Mar) | Revenue (Cr) | EBITDA (Cr) | EBITDA % | PAT (Cr) | EPS (₹) | ROE % |
|---|---|---|---|---|---|---|
| FY20 | 2,599 | 526 | 20.2% | 335 | 13.19 | 21.5% |
| FY21 | 3,238 | 856 | 26.4% | 549 | 22.18 | 27.0% |
| FY22 | 3,765 | 727 | 19.3% | 413 | 16.64 | 17.8% |
| FY23 | 4,512 | 915 | 20.3% | 517 | 21.34 | 19.6% |
| FY24 | 4,506 | 858 | 19.0% | 405 | 16.72 | 13.9% |
| FY25 | 4,482 | 948 | 21.1% | 502 | 20.68 | 13.9% |
| TTM (Q3 FY26) | 5,092 | 1,085 | 21.3% | 545 | 22.48 | ~15% |
FY24 was a disruption year: the USFDA issued a Warning Letter to the Gagillapur facility in February 2025 (observations noted December 2024), forcing a voluntary pause in manufacturing for over a month in Sep-Oct 2024. Revenue was nearly flat at ₹4,482 Cr in FY25 despite the operational headwind. What makes FY25 remarkable is that PAT recovered from ₹405 Cr to ₹502 Cr — a 24% increase — driven by a mix-shift to higher-margin finished dosages (FD share grew to 77%), gross margin expansion to ~61.7%, and sharp improvement in operating cash generation (₹866 Cr vs ₹439 Cr in FY24). This resilience validates the portfolio strategy.
The TTM trajectory into Q3 FY26 is now accelerating. Q3 FY26 delivered the company’s highest-ever quarterly revenue (₹1,388 Cr) and net profit (₹150 Cr), with EBITDA margins at 22.2%. The Gagillapur VAI (Voluntary Action Indicated) resolution, GLS capacity ramp, and the new Amphetamine ER product (180-day exclusivity in the ADHD space, ~$41M market) are contributing to volume and mix tailwinds.
| Quarterly Trend | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue (Cr) | 1,180 | 967 | 1,138 | 1,197 | 1,210 | 1,297 | 1,388 |
| EBITDA (Cr) | 259 | 203 | 230 | 252 | 247 | 278 | 308 |
| EBITDA % | 22% | 21% | 20% | 21% | 20% | 21% | 22% |
| PAT (Cr) | 135 | 97 | 118 | 152 | 113 | 131 | 150 |
| EPS (₹) | 5.56 | 4.01 | 4.85 | 6.27 | 4.64 | 5.38 | 6.19 |
We model a 10-year explicit FCF forecast anchored on WACC of 12% and terminal growth of 5%. The base case assumes: (i) revenue growing at ~16–17% in FY26E and FY27E on Gagillapur normalisation + GLS ramp, tapering to 12–14% in the outer years; (ii) EBITDA margins stabilising at 21–22%; (iii) capex moderating post the GLS build-out phase; and (iv) working capital normalisation supporting FCF conversion of ~65–70% of EBITDA by FY28E.
| Year | Revenue (Cr) | EBITDA (Cr) | EBIT (Cr) | NOPAT (Cr) | FCF (Cr) | PV of FCF (Cr) |
|---|---|---|---|---|---|---|
| FY26E | 5,700 | 1,230 | 925 | 685 | 510 | 455 |
| FY27E | 6,600 | 1,450 | 1,100 | 814 | 640 | 510 |
| FY28E | 7,450 | 1,640 | 1,265 | 936 | 780 | 556 |
| FY29E | 8,350 | 1,840 | 1,430 | 1,058 | 890 | 566 |
| FY30E | 9,300 | 2,050 | 1,610 | 1,191 | 1,010 | 574 |
| FY31E | 10,300 | 2,270 | 1,800 | 1,332 | 1,130 | 573 |
| FY32E | 11,300 | 2,490 | 1,985 | 1,469 | 1,255 | 568 |
| FY33E | 12,300 | 2,710 | 2,170 | 1,606 | 1,375 | 555 |
| FY34E | 13,300 | 2,930 | 2,355 | 1,743 | 1,495 | 539 |
| FY35E | 14,300 | 3,150 | 2,540 | 1,880 | 1,615 | 519 |
The base-case intrinsic value of ₹501 represents a ~21% discount to CMP of ₹638. However, DCF is a conservative anchor — it does not fully capture option value from: (a) peptides/CDMO via Ascelis (Senn Chemicals acquisition providing a European beachhead), (b) 180-day ADHD exclusivity product launches in FY26/27, and (c) operating leverage as GLS reaches utilisation scale. Applying a 15–20% strategic premium to the base DCF yields a fair value corridor of ₹575–600. The stock’s current P/E of ~28× trailing is at a 15% discount to the pharma sector median of 33×, providing relative valuation support.
At CMP of ₹638, Granules is in the upper end of the tactical entry zone — marginally above the core accumulate band. An investor entering here must anchor to a 2–3 year holding horizon and be comfortable with potential near-term price volatility tied to USFDA regulatory newsflow. The optimal strategy is to stagger accumulation, building a full position on dips toward ₹580–620, which aligns with 22–24× FY27E EPS of ₹26–27.
| Metric | Bear Case | Base Case | Bull Case |
|---|---|---|---|
| Revenue FY27E (Cr) | 5,600 | 6,600 | 7,400 |
| EBITDA Margin FY27E | 19% | 22% | 24% |
| PAT FY27E (Cr) | 480 | 710 | 950 |
| EPS FY27E (₹) | 19.8 | 29.3 | 39.2 |
| Target P/E | 21× | 24.5× | 24.5× |
| Target Price (₹) | 416 | 718 | 961 |
| Upside from ₹638 | −35% | +13% | +51% |
Bear case: persistent USFDA disruptions at Gagillapur or new GLS observations; slow ramp of new products; US pricing pressure steeper than expected. Base case: Gagillapur fully normalised by H1 FY26, GLS scales to ~60% utilisation, Amphetamine ER launches with partial exclusivity capture. Bull case: complete regulatory clearance, strong peptides CDMO pipeline monetisation, US OTC share gains, Europe acceleration.
| Scenario | Trigger | Implied Price | Action |
|---|---|---|---|
| Regulatory re-escalation | New Warning Letter at Gagillapur or GLS | ₹420–480 | Reassess thesis; cut on bounce |
| Earnings miss | FY27E PAT below ₹600 Cr on margin compression | ₹550–600 | Hold; re-evaluate at results |
| Bull-case priced in | P/E expands to 32–35× on exclusivity hype | ₹840–960 | Book 50%+ profits |
| Promoter dilution >3% | Sustained selling by promoters | — | Reduce on weak corporate governance signal |
| Projections | FY25A | FY26E | FY27E | FY28E | CAGR FY25–28E |
|---|---|---|---|---|---|
| Revenue (Cr) | 4,482 | 5,700 | 6,600 | 7,450 | +18.4% |
| EBITDA (Cr) | 948 | 1,230 | 1,450 | 1,640 | +19.9% |
| PAT (Cr) | 502 | 660 | 710 | 870 | +20.2% |
| EPS (₹) | 20.68 | 27.2 | 29.3 | 35.9 | +20.2% |
| EBITDA Margin | 21.1% | 21.6% | 22.0% | 22.0% | — |
| P/E (at CMP ₹638) | 30.9× | 23.5× | 21.8× | 17.8× | — |
- USFDA regulatory recurrence at Gagillapur or GLS; any new OAI/Warning Letter would be severely adverse
- US generic drug pricing pressure, particularly in core legacy molecules (ibuprofen, acetaminophen, metformin)
- Promoter holding declining trend (from 40.9% to 38.0% over last year) — governance signal risk
- Interest cost elevation (₹29 Cr/quarter) rising with net debt of ₹1,015 Cr; FCF conversion at risk if capex remains elevated
- Peptides/CDMO (Senn Chemicals) integration execution risk; European regulatory pathways complex
- Currency risk: USD/INR appreciation benefits exports but any reversal compresses realisations
- Concentration risk: North America at 79% of revenues — any US trade/tariff policy disruption for Indian pharma
- USFDA inspection clearance at Gagillapur with NAI/VAI — fully resolved status unlocks new product approvals
- Amphetamine ER commercial launch (FY26/27): 180-day exclusivity on ~$41M market is a material earnings event
- GLS utilisation ramp to 60%+: operating leverage release, target EBITDA margin 22–23%
- Ascelis Peptides first large CDMO contract announcement — re-rating catalyst for the business model
- Chantilly (Virginia) cGMP audit close-out with NAI (April 2026 audit completed with only 4 procedural observations)
- New ANDA approvals: pipeline of complex/controlled substances reduces legacy revenue concentration
- India API PLI scheme benefits; Biosecure Act-driven sourcing shift from China to Indian API/CDMO suppliers
| Company | Mkt Cap (Cr) | Revenue TTM (Cr) | EBITDA % | PAT (Cr) | P/E (TTM) | ROE % | Net D/E |
|---|---|---|---|---|---|---|---|
| Granules India | 15,490 | 5,092 | 21.3% | 545 | 28.4× | 13.9% | 0.27× |
| Divi’s Laboratories | 1,10,000 | 9,200 | 35.0% | 2,400 | 46× | 18.5% | 0.0× |
| Laurus Labs | 27,000 | 6,800 | 22.0% | 480 | 56× | 10.2% | 0.45× |
| IOL Chem & Pharma | 2,800 | 2,400 | 12.0% | 140 | 20× | 10.5% | 0.10× |
| Neuland Labs | 19,000 | 2,100 | 24.0% | 390 | 49× | 22.0% | 0.0× |
| Solara Active Pharma | 1,200 | 1,300 | 11.0% | −40 | N/M | Neg | 1.2× |
Granules trades at a meaningful discount to Divi’s, Laurus, and Neuland on P/E, despite competitive EBITDA margins and a stronger balance sheet than Laurus or Solara. The discount is partially justified by its lower ROE profile (constrained by the GLS capex cycle) and lingering USFDA regulatory overhang. As both headwinds resolve through FY26–27, a re-rating toward 30–32× FY27E EPS is plausible, which would imply a target range of ₹720–860.
The primary risk — USFDA regulatory credibility — appears to be on a mending trajectory, with the Gagillapur facility’s December 2025 inspection closing with only procedural observations (no data integrity concerns), the Virginia facility receiving NAI, and the Chantilly site completing its April 2026 audit with four Form 483 procedural items only. Each clean audit incrementally de-risks the investment case.
At CMP of ₹638, risk-reward is moderately asymmetric: ~13% upside to the base case target of ₹720, and ~51% potential in a bull-case scenario. We would aggressively add positions in the ₹560–620 band and size the position as core if USFDA issues fully resolve in H1 FY26. The stock’s 17% 1-year return (vs Nifty 50’s 5%) demonstrates earnings-driven re-rating potential that is still in progress.
